Impact of KRAS mutation status on outcomes in metastatic colon cancer patients without anti-epidermal growth factor receptor therapy

Seung Tae Kim, Kyong Hwa Park, Jun Suk Kim, Sang Won Shin, Yeul Hong Kim

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)

Abstract

Purpose: Activating mutation of the KRAS oncogene is an established negative predictor for anti-epidermal growth factor receptor (anti-EGFR) therapies in metastatic colorectal cancer (CRC). However, KRAS mutation as a prognostic factor of survival outcome remains controversial in CRC, independent of anti-EGFR therapies. Materials and Methods: We conducted a retrospective analysis of 103 CRC patients who were available for evaluation of KRAS mutation status. None of the patients analyzed had received anti-EGFR therapies. The role of KRAS mutation status was evaluated as a predictive factor for oxaliplatin or irinotecan and as a prognostic factor in CRC patients who did not receive anti-EGFR therapies. Results: Mutations in KRAS were observed in 48.5% of patients. The response for oxaliplatin-(p=0.664) and irinotecan-based (p=0.255) cytotoxic chemotherapy did not differ according to the KRAS mutation status. In addition, no significant difference in progression free survival (PFS; oxaliplatin, p=0.583 and irinotecan, p=0.426) and overall survival (OS; p=0.258) was observed between the wild and mutant type of the KRAS gene. In univariate and multivariate analyses, KRAS mutations did not have a major prognostic value regarding PFS (oxaliplatin: hazard ratio, 0.892; 95% confidence interval [CI], 0.590 to 1.347; p=0.586 and irinotecan: hazard ratio, 0.831; 95% CI, 0.524 to 1.319; p=0.433) or OS (hazard ratio, 0.754; 95% CI, 0.460 to 1.236; p=0.263). In addition, anti-vascular endothelial growth factor therapies did not affect PFS to oxaliplatin or irinotecan and OS. Conclusion: KRAS mutation is not a prognostic marker for PFS to oxaliplatin or irinotecan and OS in CRC patients who did not receive anti-EGFR therapies.

Original languageEnglish
Pages (from-to)55-62
Number of pages8
JournalCancer Research and Treatment
Volume45
Issue number1
DOIs
Publication statusPublished - 2013 Mar

Keywords

  • Anti-EGFR
  • Colorectal neoplasms
  • Kras

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Impact of KRAS mutation status on outcomes in metastatic colon cancer patients without anti-epidermal growth factor receptor therapy'. Together they form a unique fingerprint.

Cite this